MedTrace Logo

Danhong Injection in the Treatment of Unstable Angina Pectoris

NCT02007187 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2017-12-02

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of Danhong injection in the treatment of unstable angina pectoris.

Conditions

  • Unstable Angina Pectoris

Interventions

DRUG

Danhong injection

A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower

OTHER

Standard medical care

Standard medical care is in accordance with China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association

DRUG

Placebo

0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.

Sponsors & Collaborators

  • China Food and Drug Administration

    collaborator OTHER_GOV

  • China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Zhong Wang, M.D., Ph.D. · Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

  • Xian Wang, M.D. · Dongzhimen Hospital, Beijing

  • Xiao-xi Du, Professor · China Food and Drug Administration

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2017-08-31
Completion
2017-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02007187 on ClinicalTrials.gov